Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 0,43 € (-21,82 %). La médiane est de 0,43 € (-21,82 %).
| Acheter |
2 |
| Conserver |
3 |
| Vendre |
0 |
Actualités Accéder au fil d'actualités
Lyra Therapeutics files to delist from Nasdaq and seeks to suspend SEC reporting obligations
Lyra Therapeutics said it will voluntarily file a Form‑25 with the SEC on April 20, 2026, to end the listing of its common stock on Nasdaq; trading had already been suspended on March 17, 2026. The delisting is expected to take effect about ten days after filing, after which the company plans to file a Form‑15 to terminate registration under Section 12(g) and suspend reporting under Section 15(d). The stock fell 85% over the past year to $0.66 and market capitalization shrank to $1.17 million; the common shares are currently traded on the Pink Limited Market. An analysis also points to rapid cash burn by the company. » Plus sur de.investing.com
Lyra Therapeutics terminates leases in Massachusetts early amid financial pressure
According to SEC filings, Lyra Therapeutics has agreed to early terminations of leases for locations in Watertown and Waltham, paying lump-sum fees and waiving bank guarantees. For the Watertown space the company waived a security deposit of $302,514.84 and will pay $1,000,000; for Waltham it waived a $1,089,389 deposit and will pay a $1,500,000 termination fee; additionally, up to 10% of net proceeds (capped at $1,500,000) is agreed if the property is sold. The company is under severe financial pressure (market capitalization around $940,000, share price year-to-date -87.5%, free cash flow -$29 million), has halted development of LYR-210 and laid off all 28 remaining employees. Lyra is working with SSG Capital Advisors on strategic alternatives; CEO Maria Palasis and CFO Jason Cavalier will remain on as advisers. » Plus sur de.investing.com
Lyra Therapeutics reports rent payment default during wind-down
Lyra Therapeutics received a notice from RVAC over unpaid rent for office space in Waltham; outstanding claims amount to $484,431.92. The notice follows previously announced plans to cease operations and wind down; Lyra had offered a proposal to terminate the sublease before payments were stopped. The company has halted further development of LYR-210, laid off all 28 remaining employees and engaged SSG Capital Advisors to review strategic alternatives, while CEO Maria Palasis and CFO Jason Cavalier are supporting the process as advisors. InvestingPro data show rapid cash burn and rate the financial position as weak, although the current ratio still stands at 2.43. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | déc. 2025 | |
|---|---|---|
| Chiffre d'affaires | 5,97 k | - |
| Bénéfice brut | 261,66 k | - |
| Bénéfice net | -5,92 M | - |
| EBITDA | -5,81 M | - |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 382,98 k € |
Nombre d'actions | 1,77 M |
Plus haut/bas sur 52 semaines | 7,55 € - 0,000345 € |
| Dividendes | Non |
Bêta | 0,71 |
Ratio P/E | -0,01 |
Ratio PEG | 0,00 |
Ratio P/B | -0,36 |
Ratio P/S | 1,11 |
Profil de l'entreprise
Lyra Therapeutics, Inc. ist ein Unternehmen für Therapeutika in der klinischen Phase und konzentriert sich auf die Entwicklung und Vermarktung neuartiger integrierter Lösungen für die lokale Behandlung von Patienten mit Hals-, Nasen- und Ohrenkrankheiten. Die XTreo-Technologieplattform des Unternehmens ist darauf ausgelegt, Medikamente mit einer einzigen Verabreichung über einen längeren Zeitraum direkt an das betroffene Gewebe abzugeben. Zu den Produktkandidaten des Unternehmens gehören LYR-210, eine entzündungshemmende implantierbare Arzneimittelmatrix zur Behandlung von chronischer Rhinosinusitis (CRS), die sich in der klinischen Phase II befindet, sowie LYR-220 für CRS-Patienten mit und ohne Nasenpolypen. Das Unternehmen war früher als 480 Biomedical, Inc. bekannt und änderte im Juli 2018 seinen Namen in Lyra Therapeutics, Inc. Lyra Therapeutics, Inc. wurde im Jahr 2005 gegründet und hat seinen Hauptsitz in Watertown, Massachusetts.
| Nom | LYRA THERAPEUT. DL-,001 |
| PDG | Carmichael S. Roberts Jr. |
| Siège social | Watertown,
ma États-Unis |
| Site web | |
| Secteur | Consommation discrétionnaire |
| Industrie | Biens de consommation durables |
| Introduction en bourse | 01/05/2020 |
| Employés | 27 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | LYRA |
Découvrir des actifs
Les actionnaires de LYRA THERAPEUT. DL-,001 investissent également dans les actifs suivants




